Recent studies demonstrated that higher expressions of CRABP2 were likely correlated to poor prognosis and tumor progression in various cancers, including glioblastoma, EC, breast cancer, and non-small cell lung cancer, and therefore regarded as a potential biomarker for endometrial cancer malignancy (Wu et al., 2019; Egan et al., 2022; Liu et al., 2022; Fu et al., 2024). This evidence concerns the gene CRABP2 and non-small cell lung carcinoma.